• Atlas of Liquid Biopsy: Circulating Tumor Cells and Other Rare Cells in Cancer Patients’ Blood

    This book provides a wealth of images and extensive information on circulating tumor cells (CTCs) and other cells usually observed in blood from patients with cancer, such as giant macrophages, and circulating tumor microemboli (CTM).The field of “liquid biopsy” began with the analysis of CTCs in the early 2000s. In the beginning, molecular techniques were developed to detect these cells in the blood. However, it has since become clear that CTCs initially require a cytopathological analysis to be detected without false positive and negative results. After detection, molecular analysis can be subsequently performed.Cancer is an important cause of mortality, especially when detected in late stages. Even with all the advances that have been made in its treatment, cancer is still challenging, as many patients do not respond to any therapy. Many health agencies have considered early diagnosis as a feasible tool. In this context, it is of the utmost importance to know the morphology and characteristics of CTCs to determine a correct diagnosis. Currently much of the scientific community is committed to expanding our knowledge of CTCs, and this work makes a valuable contribution, presenting hundreds of cell images from patients with various types of cancer, in many different stages of disease, and after receiving various treatments.The Atlas of Liquid Biopsy: Circulating Tumor Cells and Other Rare Cells in Cancer Patients’ Blood is an essential reference guide for all physicians, biologists, biomedics, and professionals working at clinical and research laboratories, hospitals and research centers.
    • ASIN ‏ : ‎ B0969GD7FD
    • Publisher ‏ : ‎ Springer; 1st ed. 2021 edition (May 31, 2021)
    • Publication date ‏ : ‎ May 31, 2021
    • Language ‏ : ‎ English
    • Pages ‏ : ‎ 301 pages
  • Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management

    Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians

    • Publisher : Springer Nature Switzerland AG; 1st ed. 2022 edition (January 4, 2022)
    • Language : English
    • Hardcover : 315 pages
    • ISBN-10 : 303080545X
    • ISBN-13 : 978-3030805456